240 related articles for article (PubMed ID: 35144959)
1. Impact of one and two human papillomavirus (HPV) vaccine doses on community-level HPV prevalence in South African adolescent girls: study protocol and rationale for a pragmatic before-after design.
Machalek D; Rees H; Chikandiwa A; Munthali R; Travill D; Mbulawa Z; Petoumenos K; Delany-Moretlwe S; Kaldor J;
BMJ Open; 2022 Feb; 12(2):e059968. PubMed ID: 35144959
[TBL] [Abstract][Full Text] [Related]
2. Human Papillomavirus Vaccination in South Africa: Programmatic Challenges and Opportunities for Integration With Other Adolescent Health Services?
Amponsah-Dacosta E; Blose N; Nkwinika VV; Chepkurui V
Front Public Health; 2022; 10():799984. PubMed ID: 35174123
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus vaccine effect against human papillomavirus infection in Rwanda: evidence from repeated cross-sectional cervical-cell-based surveys.
Sayinzoga F; Tenet V; Heideman DAM; Sibomana H; Umulisa MC; Franceschi S; Hakizimana JD; Clifford GM; Baussano I
Lancet Glob Health; 2023 Jul; 11(7):e1096-e1104. PubMed ID: 37207683
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence.
Li X; Stander MP; Van Kriekinge G; Demarteau N
BMC Infect Dis; 2015 Dec; 15():566. PubMed ID: 26652918
[TBL] [Abstract][Full Text] [Related]
5. Implementation of a human papillomavirus vaccination demonstration project in Malawi: successes and challenges.
Msyamboza KP; Mwagomba BM; Valle M; Chiumia H; Phiri T
BMC Public Health; 2017 Jun; 17(1):599. PubMed ID: 28651574
[TBL] [Abstract][Full Text] [Related]
6. Misinformation Drives Low Human Papillomavirus Vaccination Coverage in South African Girls Attending Private Schools.
Milondzo T; Meyer JC; Dochez C; Burnett RJ
Front Public Health; 2021; 9():598625. PubMed ID: 33681125
[No Abstract] [Full Text] [Related]
7. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
Drolet M; Laprise JF; Martin D; Jit M; Bénard É; Gingras G; Boily MC; Alary M; Baussano I; Hutubessy R; Brisson M
Lancet Infect Dis; 2021 Nov; 21(11):1598-1610. PubMed ID: 34245682
[TBL] [Abstract][Full Text] [Related]
8. Vaccine Hesitancy Drives Low Human Papillomavirus Vaccination Coverage in Girls Attending Public Schools in South Africa.
Khosa LA; Meyer JC; Motshwane FMM; Dochez C; Burnett RJ
Front Public Health; 2022; 10():860809. PubMed ID: 35685759
[TBL] [Abstract][Full Text] [Related]
9. National introduction of human papillomavirus (HPV) vaccine in Tanzania: Programmatic decision-making and implementation.
Mphuru A; Li AJ; Kyesi F; Mwengee W; Mazige F; Nshunju R; Shayo B; Giattas MR; Loharikar A; Lyimo D
Vaccine; 2022 Mar; 40 Suppl 1(Suppl 1):A2-A9. PubMed ID: 33962839
[TBL] [Abstract][Full Text] [Related]
10. Rationale and design of a double-blind randomized non-inferiority clinical trial to evaluate one or two doses of vaccine against human papillomavirus including an epidemiologic survey to estimate vaccine efficacy: The Costa Rica ESCUDDO trial.
Porras C; Sampson JN; Herrero R; Gail MH; Cortés B; Hildesheim A; Cyr J; Romero B; Schiller JT; Montero C; Pinto LA; Schussler J; Coronado K; Sierra MS; Kim JJ; Torres CM; Carvajal L; Wagner S; Campos NG; Ocampo R; Kemp TJ; Zuniga M; Lowy DR; Avila C; Chanock S; Castrillo A; Estrada Y; Barrientos G; Monge C; Oconitrillo MY; Kreimer AR
Vaccine; 2022 Jan; 40(1):76-88. PubMed ID: 34857420
[TBL] [Abstract][Full Text] [Related]
11. Potential benefit of extended dose schedules of human papillomavirus vaccination in the context of scarce resources and COVID-19 disruptions in low-income and middle-income countries: a mathematical modelling analysis.
Bénard É; Drolet M; Laprise JF; Jit M; Prem K; Boily MC; Brisson M
Lancet Glob Health; 2023 Jan; 11(1):e48-e58. PubMed ID: 36521952
[TBL] [Abstract][Full Text] [Related]
12. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
13. Potential population-level effectiveness of one-dose HPV vaccination in low-income and middle-income countries: a mathematical modelling analysis.
Bénard É; Drolet M; Laprise JF; Gingras G; Jit M; Boily MC; Bloem P; Brisson M
Lancet Public Health; 2023 Oct; 8(10):e788-e799. PubMed ID: 37777288
[TBL] [Abstract][Full Text] [Related]
14. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study.
Tabrizi SN; Brotherton JM; Kaldor JM; Skinner SR; Liu B; Bateson D; McNamee K; Garefalakis M; Phillips S; Cummins E; Malloy M; Garland SM
Lancet Infect Dis; 2014 Oct; 14(10):958-66. PubMed ID: 25107680
[TBL] [Abstract][Full Text] [Related]
15. Options for design of real-world impact studies of single-dose vaccine schedules.
Franceschi S; Clifford GM; Baussano I
Vaccine; 2018 Aug; 36(32 Pt A):4816-4822. PubMed ID: 29571973
[TBL] [Abstract][Full Text] [Related]
16. Combining cervical cancer screening for mothers with schoolgirl vaccination during human papillomavirus (HPV) vaccine implementation in South Africa: results from the VACCS1 and VACCS2 trials.
Dreyer G; Botha MH; Snyman LC; Visser C; Burden R; Laubscher N; Grond B; Richter K; Becker PJ; Harvey J; van der Merwe FH
Int J Gynecol Cancer; 2022 May; 32(5):592-598. PubMed ID: 35078829
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus (HPV) vaccine introduction in Sikkim state: Best practices from the first statewide multiple-age cohort HPV vaccine introduction in India-2018-2019.
Ahmed D; VanderEnde K; Harvey P; Bhatnagar P; Kaur N; Roy S; Singh N; Denzongpa P; Haldar P; Loharikar A
Vaccine; 2022 Mar; 40 Suppl 1(Suppl 1):A17-A25. PubMed ID: 34429233
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Bivalent, Quadrivalent, and Nonavalent HPV Vaccination in South Africa.
Michaeli DT; Stoycheva S; Marcus SM; Zhang W; Michaeli JC; Michaeli T
Clin Drug Investig; 2022 Apr; 42(4):333-343. PubMed ID: 35294726
[TBL] [Abstract][Full Text] [Related]
19. The Vaccine and Cervical Cancer Screen project 2 (VACCS 2): Linking cervical cancer screening to a two-dose HPV vaccination schedule in the South-West District of Tshwane, Gauteng, South Africa.
Snyman LC; Dreyer G; Visser C; Botha MH; van der Merwe FH
S Afr Med J; 2015 Mar; 105(3):191-4. PubMed ID: 26294825
[TBL] [Abstract][Full Text] [Related]
20. Long-term human papillomavirus vaccination effectiveness and immunity in Rwandan women living with and without HIV: a study protocol.
Murenzi G; Shumbusho F; Hansen N; Munyaneza A; Gage JC; Muhoza B; Kanyabwisha F; Pierz A; Tuyisenge P; Anastos K; Castle PE
BMJ Open; 2022 Aug; 12(8):e061650. PubMed ID: 36008069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
